JASPER THERAPEUTICS INC (JSPR) Stock Earnings & Estimates
USA - NASDAQ:JSPR - US4718712023 - Common Stock
2.32 USD
-0.08 (-3.33%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 343.32% | N/A 86.46% | N/A -73.43% | N/A 162.83% | |||||||
| EBITDA YoY % growth | N/A | N/A | -36.456M | -50.221M -37.76% | -67.753M -34.91% | -74.866M -10.50% | N/A -24.70% | N/A -24.68% | N/A -17.67% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.71M | -20.683M -339.13% | -36.833M -78.08% | -51.196M -38.99% | -68.861M -34.50% | -76.239M -10.71% | N/A -27.50% | N/A -11.65% | N/A -23.17% | N/A 14.89% | N/A 65.27% | N/A 196.51% | N/A -224.77% | N/A 192.82% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -10.30 55.00% | -6.20 39.81% | -4.86 21.61% | N/A -4.91% | N/A 26.37% | N/A 6.94% | N/A 9.85% | N/A 56.38% | N/A 238.61% | N/A -141.25% | N/A 68.83% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.28 -3.49% | -1.01 37.48% | -0.76 46.43% | -0.81 53.63% | -0.98 23.96% | -1.01 0.74% | -0.52 31.13% | -0.51 36.79% | -0.52 46.69% | -0.53 47.24% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||||
| EBITDA Q2Q % growth | -24.072M -28.31% | -22.981M 3.90% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -25.1M -26.20% | -22.245M 12.02% | -26.25M -20.40% | -27.955M -22.45% | -29.912M -19.17% | -32.006M -43.88% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.74 -79.38% | -1.35 | -0.39 | -28.61% |
| Q1 2025 Q2Q % growth | -1.41 -36.89% | -1.34 | -0.07 | -5.32% |
| Q4 2024 Q2Q % growth | -1.62 -8.00% | -1.25 | -0.37 | -29.09% |
| Q3 2024 Q2Q % growth | -1.24 22.50% | -1.09 | -0.15 | -13.47% |
| Q2 2024 Q2Q % growth | -0.97 35.33% | -1.11 | 0.14 | 12.67% |
| Q1 2024 Q2Q % growth | -1.03 35.63% | -1.25 | 0.22 | 17.57% |
| Q4 2023 Q2Q % growth | -1.50 58.33% | -1.65 | 0.15 | 8.94% |
| Q3 2023 Q2Q % growth | -1.60 50.00% | -1.58 | -0.02 | -1.04% |
| Q2 2023 Q2Q % growth | -1.50 48.28% | -1.53 | 0.03 | 1.83% |
| Q1 2023 Q2Q % growth | -1.60 -166.67% | -1.66 | 0.06 | 3.41% |
| Q4 2022 Q2Q % growth | -3.60 54.43% | -3.67 | 0.07 | 1.96% |
| Q3 2022 Q2Q % growth | -3.20 84.24% | -3.49 | 0.29 | 8.40% |
| Q2 2022 Q2Q % growth | -2.90 | -3.20 | 0.30 | 9.26% |
| Q1 2022 Q2Q % growth | -0.60 | -3.57 | 2.97 | 83.19% |
| Q4 2021 Q2Q % growth | -7.90 | -3.50 | -4.40 | -125.48% |
| Q3 2021 Q2Q % growth | -20.30 | -2.82 | -17.48 | -620.43% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 1.94% | 0% | 4.22% |
| Revenue | N/A | N/A | N/A | -100% |